Rejuvenate Bio

Rejuvenate Bio is one of the few aging companies with a credible path to revenue before it ever runs a human longevity trial, and 2026 gave the thesis its strongest external validation yet: in June 2026 the company closed a $6M financing and entered a strategic R&D collaboration with Merck Animal Health, the kind of Big Pharma imprimatur that most gene-therapy startups spend a decade chasing. The strategy is disciplined — use the veterinary market, where regulatory timelines are shorter and endpoints are cheaper, as the proving ground for the same single-dose AAV combination gene therapies (FGF21, soluble TGF-beta receptor 2, alpha-Klotho) it intends to translate to humans. RJB-01 for canine heart failure and RJB-02 for canine osteoarthritis attack conditions with large addressable dog populations and no disease-modifying options, and a companion-animal win generates both cash and clinical evidence that de-risks the human programs. The George Church pedigree (Harvard, the Wyss Institute) gives it scientific credibility disproportionate to its ~$14.6M raised, and a separate $4M CIRM grant for RJB-0402 in arrhythmogenic cardiomyopathy shows non-dilutive capital flowing toward the platform's rare-disease adjacencies. Multi-gene "reprogramming toward youth" is a bolder bet than single-target biology, and Rejuvenate is one of the only teams carrying it from mouse data into real animals with a partner that can commercialize.